FdaApplication
NDA 207621
Identifiers
- fda_app_no: NDA207621
Properties
| Property | Value |
|---|---|
| applicant_name | PFIZER INC |
| application_type | NDA |
| approval_date | 2016-08-19 |
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE | 3.6MG;30MG | CAPSULE, EXTENDED RELEASE;ORAL |
| TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE | 7.2MG;60MG | CAPSULE, EXTENDED RELEASE;ORAL |
| TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE | 9.6MG;80MG | CAPSULE, EXTENDED RELEASE;ORAL |
| TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE | 4.8MG;40MG | CAPSULE, EXTENDED RELEASE;ORAL |
| TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE | 1.2MG;10MG | CAPSULE, EXTENDED RELEASE;ORAL |
| TROXYCA ER | NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE | 2.4MG;20MG | CAPSULE, EXTENDED RELEASE;ORAL |
6 products